ATP - CAS 987-65-5
Catalog number: 987-65-5
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C10H14N5O13P3·2Na
Molecular Weight:
551.14
COA:
Inquire
Targets:
P2X Receptor
Description:
ATP is a disodium salt form of adenosine-triphosphate which is a multifunctional nucleoside triphosphate.
Purity:
>98%
Synonyms:
Adenosine-Triphosphate
MSDS:
Inquire
InChIKey:
TTWYZDPBDWHJOR-IDIVVRGQSA-L
InChI:
InChI=1S/C10H16N5O13P3.2Na/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(26-10)1-25-30(21,22)28-31(23,24)27-29(18,19)20;;/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H,23,24)(H2,11,12,13)(H2,18,19,20);;/q;2*+1/p-2/t4-,6-,7-,10-;;/m1../s1
Canonical SMILES:
C1=NC2=C(C(=N1)N)N=CN2C3C(C(C(O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O.[Na+].[Na+]
1.Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial.
Stamelou M;Reuss A;Pilatus U;Magerkurth J;Niklowitz P;Eggert KM;Krisp A;Menke T;Schade-Brittinger C;Oertel WH;Höglinger GU Mov Disord. 2008 May 15;23(7):942-949. doi: 10.1002/mds.22023.
Mitochondrial complex I appears to be dysfunctional in progressive supranuclear palsy (PSP). Coenzyme Q(10) (CoQ(10)) is a physiological cofactor of complex I. Therefore, we evaluated the short-term effects of CoQ(10) in PSP. We performed a double-blind, randomized, placebo-controlled, phase II trial, including 21 clinically probable PSP patients (stage < or = III) to receive a liquid nanodispersion of CoQ(10) (5 mg/kg/day) or matching placebo. Over a 6-week period, we determined the change in CoQ(10) serum concentration, cerebral energy metabolites (by (31)P- and (1)H-magnetic resonance spectroscopy), motor and neuropsychological dysfunction (PSP rating scale, UPDRS III, Hoehn and Yahr stage, Frontal Assessment Battery, Mini Mental Status Examination, Montgomery Asberg Depression Scale). CoQ(10) was safe and well tolerated. In patients receiving CoQ(10) compared to placebo, the concentration of low-energy phosphates (adenosine-diphosphate, unphosphorylated creatine) decreased. Consequently, the ratio of high-energy phosphates to low-energy phosphates (adenosine-triphosphate to adenosine-diphosphate, phospho-creatine to unphosphorylated creatine) increased. These changes were significant in the occipital lobe and showed a consistent trend in the basal ganglia.
2.Protective effect of oxysophoridine on cerebral ischemia/reperfusion injury in mice.
Wang H;Li Y;Jiang N;Chen X;Zhang Y;Zhang K;Wang T;Hao Y;Ma L;Zhao C;Wang Y;Sun T;Yu J Neural Regen Res. 2013 May 25;8(15):1349-59. doi: 10.3969/j.issn.1673-5374.2013.15.001.
Oxysophoridine, a new alkaloid extracted from Sophora alopecuroides L., has been shown to have a protective effect against ischemic brain damage. In this study, a focal cerebral ischemia/reperfusion injury model was established using middle cerebral artery occlusion in mice. Both 62.5, 125, and 250 mg/kg oxysophoridine, via intraperitoneal injection, and 6 mg/kg nimodipine, via intragastric administration, were administered daily for 7 days before modeling. After 24 hours of reperfusion, mice were tested for neurological deficit, cerebral infarct size was assessed and brain tissue was collected. Results showed that oxysophoridine at 125, 250 mg/kg and 6 mg/kg nimodipine could reduce neurological deficit scores, cerebral infarct size and brain water content in mice. These results provided evidence that oxysophoridine plays a protective role in cerebral ischemia/reperfusion injury. In addition, oxysophoridine at 62.5, 125, and 250 mg/kg and 6 mg/kg nimodipine increased adenosine-triphosphate content, and decreased malondialdehyde and nitric oxide content. These compounds enhanced the activities of glutathione-peroxidase, superoxide dismutase, catalase, and lactate dehydrogenase, and decreased the activity of nitric oxide synthase.
3.Energy reserves in transplanted and sham-operated carciac tissue=.
Medzihradsky F;Carr EA;Nandhasri PS;Dufek JH;Kahn DR Res Commun Chem Pathol Pharmacol. 1975 Feb;10(2):337-50.
Tissue levels of creatine phosphate (CP), creatine, adenosine-triphosphate(ATP), inorganic phosphate (Pi), glycogen, glucose and lactate were determined in heterotopically transplanted and recipient hearts as well as in the myocardium of sham-operated rabbitsmthe ATPase activity in these tissues was also estimatedmthe results revealed no biochemical indication of ischemic conditions in the transplanted organs relative to the other investigated tissue. The tissue levels of CP in the donor heart were even higher then in both the recipient and sham-operated organs. The concentrations of the other above listed compounds in all the studied tissue were similar throughout the first 5 post-operative days. The effect of surgery was manifested in decreased levels of CP, still prevailing 3 days post-operative in all of the investigated tissue. However, on the fifth day after surgery, the tissue concentration of CP showed a trend toward recovery. The activity of Na,K-ATPase in both donor and recipient hearts was similar. One day after surgery, the activity of the Mg-ATPase was 27% lower relative to its value on days 3 and 5 post-operatively. However no correlation was obtained between the change in Mg-ATPase and tissue concentrations of ATP.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related P2X Receptor Products


CAS 870061-27-1 A 839977

A 839977
(CAS: 870061-27-1)

A-839977 is a novel and selective P2X7 antagonist. It blocks BzATP-evoked calcium influx at recombinant human, rat and mouse P2X7 receptors with IC50 values 20,...

CAS 987-65-5 ATP

ATP
(CAS: 987-65-5)

ATP is a disodium salt form of adenosine-triphosphate which is a multifunctional nucleoside triphosphate.

CAS 1050670-85-3 Ro 51

Ro 51
(CAS: 1050670-85-3)

Ro 51 is a potent and selective dual antagonist of purinoceptor subtypes P2X3 and P2X2/3 (IC50 values are 2 and 5 nM for rP2X3 and hP2X2/3 respectively), withou...

CAS 873398-67-5 TC-P 262

TC-P 262
(CAS: 873398-67-5)

TC-P 262 is a selective P2X3 and P2X2/3 receptor antagonist (pIC50 = 7.39 and 6.68, respectively). TC-P 262 has no detectable activity at P2X1, P2X2, P2X4 and P...

CAS 100020-57-3 2-Methylthioadenosine triphosphate tetrasodium salt

2-Methylthioadenosine triphosphate tetra
(CAS: 100020-57-3)

2-Methylthioadenosine triphosphate tetrasodium salt, an ATP analogue, is a potent P2-purinoceptor agonist affecting cell proliferation and apoptosis, and cytoki...

CAS 1026582-88-6 RO-3

RO-3
(CAS: 1026582-88-6)

RO-3 is a selective homomeric P2X3 and heteromeric P2X2/3 receptor antagonist (pIC50 values are 7.0 and 5.9 respectively). RO-3 is used in a combination of comp...

CAS 127191-97-3 KN-62

KN-62
(CAS: 127191-97-3)

KN-62 suppresses the A23187-induced autophosphorylation of Ca2+/CaM kinase in PC12 D cells.

CAS 111150-22-2 NF 110

NF 110
(CAS: 111150-22-2)

NF 110 is a P2X3 receptor antagonist with Ki value of 36nM. It shows antitumor activity against several tumor types.

Chemical Structure

CAS 987-65-5 ATP

Quick Inquiry

Verification code

Featured Items